Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities

(2017) Eric T. Wong et al.   Journal of the National Comprehensive Cancer Network

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme

(2013) Yasushi Soda et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases

(2012) S De Bruyne et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy

(2011) R. G. Bagley et al.   CLINICAL CANCER RESEARCH

Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects

(2011) Titti Martinsson-Niskanen et al.   CLINICAL THERAPEUTICS

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Perfusion CT Imaging of Brain Tumors: An Overview

(2010) R. Jain   AMERICAN JOURNAL OF NEURORADIOLOGY

Reproducibility of Perfusion Parameters in Dynamic Contrast-Enhanced MRI of Lung and Liver Tumors: Effect on Estimates of Patient Sample Size in Clinical Trials and on Individual Patient Responses

(2010) Chaan S. Ng et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Anti-Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation

(2010) L. Coenegrachts et al.   CANCER RESEARCH

PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth

(2010) Carlos Bais et al.   CELL

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

(2010) Sara Van de Veire et al.   CELL

Expression of placenta growth factor: An independent factor for prediction of progression and prognosis of oral cancer

(2010) Shih-Jung Cheng et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study

(2010) J. J. Vredenburgh et al.   ONCOLOGIST

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY